Corporate Profile
Taxus Cardium Pharmaceuticals is an advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics including Generx®, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of Cardiac Microvascular Insufficiency due to advancing coronary artery disease, and Excellagen®, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics.
Stock Quote
CRXM (Common)
ExchangeOTC BB (US Dollar)
Price$0.54
Change (%)0.00 (0.00%)
Volume7,868
Data as of 04/24/14 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: 03NA000000CRXM
Recent News
DateTitle 
04/15/14Taxus Cardium Presents Year-End 2013 Financial Results And Recent DevelopmentsPrinter Friendly Version
03/17/14Cardium Becomes Taxus Cardium Pharmaceuticals Group In Connection With Strategic Collaboration And Funding With Shanxi Taxus PharmaceuticalsPrinter Friendly Version
03/03/14Cardium Announces Strategic Collaboration And Funding With Taxus Pharmaceuticals To Support Commercial Development of Advanced Regenerative Therapeutics Printer Friendly Version
01/27/14Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical FindingsPrinter Friendly Version
Primary IR Contact
Shareholder Services
Corporate Communications/Investor Relations
11750 Sorrento Valley Road
San Diego, CA 92121

Phone: 858-436-1018
E-mail: investorrelations@cardiumthx.com


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.